nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC22A3—prostate cancer	0.533	1	CbGaD
Methamphetamine—SLC22A3—Estradiol—prostate cancer	0.0854	0.539	CbGbCtD
Methamphetamine—CYP2D6—Bicalutamide—prostate cancer	0.0369	0.233	CbGbCtD
Methamphetamine—CYP2D6—Abiraterone—prostate cancer	0.0305	0.193	CbGbCtD
Methamphetamine—Cardio-respiratory arrest—Abiraterone—prostate cancer	0.0087	0.0946	CcSEcCtD
Methamphetamine—CYP2D6—Doxorubicin—prostate cancer	0.00565	0.0356	CbGbCtD
Methamphetamine—SLC18A2—prostate gland—prostate cancer	0.00227	0.0552	CbGeAlD
Methamphetamine—SLC18A1—lymph node—prostate cancer	0.00227	0.0552	CbGeAlD
Methamphetamine—CYP2D6—urine—prostate cancer	0.00211	0.0514	CbGeAlD
Methamphetamine—Erectile dysfunction—Estramustine—prostate cancer	0.00185	0.0201	CcSEcCtD
Methamphetamine—Erectile dysfunction—Nilutamide—prostate cancer	0.00164	0.0178	CcSEcCtD
Methamphetamine—Erectile dysfunction—Flutamide—prostate cancer	0.00163	0.0178	CcSEcCtD
Methamphetamine—SLC22A3—prostate gland—prostate cancer	0.00162	0.0393	CbGeAlD
Methamphetamine—MAOB—prostate gland—prostate cancer	0.0015	0.0364	CbGeAlD
Methamphetamine—Erectile dysfunction—Degarelix—prostate cancer	0.00146	0.0159	CcSEcCtD
Methamphetamine—SLC22A3—seminal vesicle—prostate cancer	0.00137	0.0333	CbGeAlD
Methamphetamine—MAOA—prostate gland—prostate cancer	0.00128	0.031	CbGeAlD
Methamphetamine—MAOB—seminal vesicle—prostate cancer	0.00126	0.0308	CbGeAlD
Methamphetamine—ADRA2C—prostate gland—prostate cancer	0.00123	0.0298	CbGeAlD
Methamphetamine—Erectile dysfunction—Bicalutamide—prostate cancer	0.00118	0.0129	CcSEcCtD
Methamphetamine—SLC22A5—prostate gland—prostate cancer	0.00117	0.0286	CbGeAlD
Methamphetamine—SLC22A3—renal system—prostate cancer	0.0011	0.0268	CbGeAlD
Methamphetamine—SLC22A3—urethra—prostate cancer	0.00108	0.0263	CbGeAlD
Methamphetamine—MAOA—seminal vesicle—prostate cancer	0.00108	0.0263	CbGeAlD
Methamphetamine—ADRA2C—seminal vesicle—prostate cancer	0.00104	0.0252	CbGeAlD
Methamphetamine—Insomnia—Estramustine—prostate cancer	0.00103	0.0112	CcSEcCtD
Methamphetamine—Palpitations—Estradiol valerate/Dienogest—prostate cancer	0.00103	0.0112	CcSEcCtD
Methamphetamine—MAOB—renal system—prostate cancer	0.00102	0.0248	CbGeAlD
Methamphetamine—Psychotic disorder—Goserelin—prostate cancer	0.00101	0.011	CcSEcCtD
Methamphetamine—Insomnia—Abiraterone—prostate cancer	0.001	0.0109	CcSEcCtD
Methamphetamine—MAOB—urethra—prostate cancer	0.001	0.0244	CbGeAlD
Methamphetamine—SLC18A2—testis—prostate cancer	0.001	0.0243	CbGeAlD
Methamphetamine—SLC22A5—seminal vesicle—prostate cancer	0.000994	0.0242	CbGeAlD
Methamphetamine—Palpitations—Degarelix—prostate cancer	0.000979	0.0107	CcSEcCtD
Methamphetamine—ADRA2A—prostate gland—prostate cancer	0.000979	0.0238	CbGeAlD
Methamphetamine—Dyspepsia—Abiraterone—prostate cancer	0.000976	0.0106	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Abiraterone—prostate cancer	0.000957	0.0104	CcSEcCtD
Methamphetamine—Constipation—Abiraterone—prostate cancer	0.000948	0.0103	CcSEcCtD
Methamphetamine—Insomnia—Nilutamide—prostate cancer	0.000916	0.00996	CcSEcCtD
Methamphetamine—Insomnia—Flutamide—prostate cancer	0.000912	0.00992	CcSEcCtD
Methamphetamine—Dyspepsia—Nilutamide—prostate cancer	0.000891	0.0097	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Nilutamide—prostate cancer	0.000874	0.00951	CcSEcCtD
Methamphetamine—MAOA—renal system—prostate cancer	0.00087	0.0212	CbGeAlD
Methamphetamine—Urticaria—Estrone—prostate cancer	0.000866	0.00942	CcSEcCtD
Methamphetamine—Constipation—Nilutamide—prostate cancer	0.000866	0.00942	CcSEcCtD
Methamphetamine—Constipation—Flutamide—prostate cancer	0.000862	0.00938	CcSEcCtD
Methamphetamine—MAOA—urethra—prostate cancer	0.000854	0.0208	CbGeAlD
Methamphetamine—Dyspepsia—Estradiol valerate/Dienogest—prostate cancer	0.000837	0.00911	CcSEcCtD
Methamphetamine—ADRA2C—renal system—prostate cancer	0.000836	0.0203	CbGeAlD
Methamphetamine—Tachycardia—Cabazitaxel—prostate cancer	0.000832	0.00905	CcSEcCtD
Methamphetamine—ADRA2A—seminal vesicle—prostate cancer	0.000828	0.0201	CbGeAlD
Methamphetamine—Erectile dysfunction—Goserelin—prostate cancer	0.000823	0.00896	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Estradiol valerate/Dienogest—prostate cancer	0.000821	0.00894	CcSEcCtD
Methamphetamine—ADRA2C—urethra—prostate cancer	0.000821	0.02	CbGeAlD
Methamphetamine—Insomnia—Degarelix—prostate cancer	0.000818	0.0089	CcSEcCtD
Methamphetamine—SLC22A5—renal system—prostate cancer	0.000801	0.0195	CbGeAlD
Methamphetamine—SLC22A5—urethra—prostate cancer	0.000787	0.0191	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Degarelix—prostate cancer	0.000781	0.0085	CcSEcCtD
Methamphetamine—Diarrhoea—Estramustine—prostate cancer	0.000781	0.00849	CcSEcCtD
Methamphetamine—Constipation—Degarelix—prostate cancer	0.000773	0.00842	CcSEcCtD
Methamphetamine—Diarrhoea—Abiraterone—prostate cancer	0.000758	0.00825	CcSEcCtD
Methamphetamine—SLC6A3—testis—prostate cancer	0.000756	0.0184	CbGeAlD
Methamphetamine—Urticaria—Estradiol valerate/Dienogest—prostate cancer	0.000756	0.00822	CcSEcCtD
Methamphetamine—Dyspepsia—Cabazitaxel—prostate cancer	0.00075	0.00816	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Cabazitaxel—prostate cancer	0.000736	0.008	CcSEcCtD
Methamphetamine—Constipation—Cabazitaxel—prostate cancer	0.000729	0.00793	CcSEcCtD
Methamphetamine—SLC18A2—lymph node—prostate cancer	0.000725	0.0176	CbGeAlD
Methamphetamine—Dizziness—Estrone—prostate cancer	0.000721	0.00784	CcSEcCtD
Methamphetamine—Urticaria—Degarelix—prostate cancer	0.000719	0.00782	CcSEcCtD
Methamphetamine—Headache—Estramustine—prostate cancer	0.000715	0.00778	CcSEcCtD
Methamphetamine—SLC22A3—testis—prostate cancer	0.000712	0.0173	CbGeAlD
Methamphetamine—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.000701	0.00763	CcSEcCtD
Methamphetamine—Diarrhoea—Nilutamide—prostate cancer	0.000693	0.00754	CcSEcCtD
Methamphetamine—Diarrhoea—Flutamide—prostate cancer	0.00069	0.0075	CcSEcCtD
Methamphetamine—Headache—Estrone—prostate cancer	0.000683	0.00743	CcSEcCtD
Methamphetamine—Phenelzine—CYP3A43—prostate cancer	0.000681	0.111	CrCbGaD
Methamphetamine—Dizziness—Nilutamide—prostate cancer	0.00067	0.00728	CcSEcCtD
Methamphetamine—Dizziness—Flutamide—prostate cancer	0.000667	0.00725	CcSEcCtD
Methamphetamine—Hypersensitivity—Degarelix—prostate cancer	0.000666	0.00725	CcSEcCtD
Methamphetamine—Insomnia—Bicalutamide—prostate cancer	0.000661	0.00719	CcSEcCtD
Methamphetamine—MAOB—testis—prostate cancer	0.000659	0.016	CbGeAlD
Methamphetamine—ADRA2A—urethra—prostate cancer	0.000655	0.0159	CbGeAlD
Methamphetamine—Dyspepsia—Bicalutamide—prostate cancer	0.000643	0.007	CcSEcCtD
Methamphetamine—Headache—Nilutamide—prostate cancer	0.000634	0.0069	CcSEcCtD
Methamphetamine—Headache—Flutamide—prostate cancer	0.000631	0.00687	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Bicalutamide—prostate cancer	0.000631	0.00687	CcSEcCtD
Methamphetamine—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.000629	0.00684	CcSEcCtD
Methamphetamine—Hypersensitivity—Cabazitaxel—prostate cancer	0.000628	0.00683	CcSEcCtD
Methamphetamine—Constipation—Bicalutamide—prostate cancer	0.000625	0.0068	CcSEcCtD
Methamphetamine—Diarrhoea—Degarelix—prostate cancer	0.000619	0.00673	CcSEcCtD
Methamphetamine—SLC6A2—testis—prostate cancer	0.00061	0.0148	CbGeAlD
Methamphetamine—Erectile dysfunction—Mitoxantrone—prostate cancer	0.000608	0.00662	CcSEcCtD
Methamphetamine—Dizziness—Degarelix—prostate cancer	0.000598	0.00651	CcSEcCtD
Methamphetamine—Headache—Estradiol valerate/Dienogest—prostate cancer	0.000596	0.00648	CcSEcCtD
Methamphetamine—Diarrhoea—Cabazitaxel—prostate cancer	0.000583	0.00634	CcSEcCtD
Methamphetamine—Urticaria—Bicalutamide—prostate cancer	0.000581	0.00632	CcSEcCtD
Methamphetamine—Headache—Degarelix—prostate cancer	0.000567	0.00616	CcSEcCtD
Methamphetamine—Dizziness—Cabazitaxel—prostate cancer	0.000563	0.00613	CcSEcCtD
Methamphetamine—MAOA—testis—prostate cancer	0.000562	0.0137	CbGeAlD
Methamphetamine—Palpitations—Goserelin—prostate cancer	0.000551	0.00599	CcSEcCtD
Methamphetamine—Palpitations—Conjugated Estrogens—prostate cancer	0.000545	0.00593	CcSEcCtD
Methamphetamine—ADRA2C—testis—prostate cancer	0.00054	0.0131	CbGeAlD
Methamphetamine—Euphoric mood—Prednisone—prostate cancer	0.000539	0.00587	CcSEcCtD
Methamphetamine—Hypersensitivity—Bicalutamide—prostate cancer	0.000538	0.00586	CcSEcCtD
Methamphetamine—Headache—Cabazitaxel—prostate cancer	0.000534	0.00581	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.000533	0.0058	CcSEcCtD
Methamphetamine—Constipation—Ethinyl Estradiol—prostate cancer	0.000528	0.00575	CcSEcCtD
Methamphetamine—Pseudoephedrine—IL2—prostate cancer	0.000525	0.0857	CrCbGaD
Methamphetamine—SLC22A5—testis—prostate cancer	0.000518	0.0126	CbGeAlD
Methamphetamine—CYP2D6—renal system—prostate cancer	0.000517	0.0126	CbGeAlD
Methamphetamine—SLC22A3—lymph node—prostate cancer	0.000516	0.0126	CbGeAlD
Methamphetamine—Diarrhoea—Bicalutamide—prostate cancer	0.0005	0.00544	CcSEcCtD
Methamphetamine—Tachycardia—Goserelin—prostate cancer	0.000496	0.0054	CcSEcCtD
Methamphetamine—Tachycardia—Conjugated Estrogens—prostate cancer	0.000492	0.00535	CcSEcCtD
Methamphetamine—Urticaria—Ethinyl Estradiol—prostate cancer	0.000491	0.00534	CcSEcCtD
Methamphetamine—Dizziness—Bicalutamide—prostate cancer	0.000483	0.00526	CcSEcCtD
Methamphetamine—MAOB—lymph node—prostate cancer	0.000477	0.0116	CbGeAlD
Methamphetamine—Tremor—Estradiol—prostate cancer	0.000463	0.00503	CcSEcCtD
Methamphetamine—Insomnia—Goserelin—prostate cancer	0.00046	0.005	CcSEcCtD
Methamphetamine—Headache—Bicalutamide—prostate cancer	0.000458	0.00498	CcSEcCtD
Methamphetamine—Insomnia—Conjugated Estrogens—prostate cancer	0.000456	0.00496	CcSEcCtD
Methamphetamine—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000455	0.00495	CcSEcCtD
Methamphetamine—Agitation—Estradiol—prostate cancer	0.000454	0.00494	CcSEcCtD
Methamphetamine—Dyspepsia—Goserelin—prostate cancer	0.000448	0.00487	CcSEcCtD
Methamphetamine—Psychotic disorder—Prednisone—prostate cancer	0.000445	0.00484	CcSEcCtD
Methamphetamine—Dyspepsia—Conjugated Estrogens—prostate cancer	0.000443	0.00482	CcSEcCtD
Methamphetamine—SLC6A2—lymph node—prostate cancer	0.000442	0.0108	CbGeAlD
Methamphetamine—L-Phenylalanine—TH—prostate cancer	0.000437	0.0713	CrCbGaD
Methamphetamine—Palpitations—Estradiol—prostate cancer	0.000436	0.00475	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000435	0.00473	CcSEcCtD
Methamphetamine—Constipation—Goserelin—prostate cancer	0.000435	0.00473	CcSEcCtD
Methamphetamine—ADRA2A—testis—prostate cancer	0.000431	0.0105	CbGeAlD
Methamphetamine—Constipation—Conjugated Estrogens—prostate cancer	0.000431	0.00469	CcSEcCtD
Methamphetamine—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000423	0.0046	CcSEcCtD
Methamphetamine—Dexfenfluramine—CYP2A6—prostate cancer	0.000421	0.0688	CrCbGaD
Methamphetamine—Ephedrine—ACHE—prostate cancer	0.00041	0.0669	CrCbGaD
Methamphetamine—Dizziness—Ethinyl Estradiol—prostate cancer	0.000409	0.00445	CcSEcCtD
Methamphetamine—MAOA—lymph node—prostate cancer	0.000407	0.00991	CbGeAlD
Methamphetamine—Urticaria—Goserelin—prostate cancer	0.000404	0.00439	CcSEcCtD
Methamphetamine—Urticaria—Conjugated Estrogens—prostate cancer	0.0004	0.00435	CcSEcCtD
Methamphetamine—Tachycardia—Estradiol—prostate cancer	0.000393	0.00428	CcSEcCtD
Methamphetamine—ADRA2C—lymph node—prostate cancer	0.000392	0.00953	CbGeAlD
Methamphetamine—Headache—Ethinyl Estradiol—prostate cancer	0.000387	0.00421	CcSEcCtD
Methamphetamine—Phenformin—SLC22A1—prostate cancer	0.000379	0.062	CrCbGaD
Methamphetamine—SLC22A5—lymph node—prostate cancer	0.000375	0.00913	CbGeAlD
Methamphetamine—Hypersensitivity—Goserelin—prostate cancer	0.000375	0.00408	CcSEcCtD
Methamphetamine—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000371	0.00404	CcSEcCtD
Methamphetamine—Tachycardia—Mitoxantrone—prostate cancer	0.000367	0.00399	CcSEcCtD
Methamphetamine—Insomnia—Estradiol—prostate cancer	0.000365	0.00397	CcSEcCtD
Methamphetamine—Erectile dysfunction—Prednisone—prostate cancer	0.000363	0.00395	CcSEcCtD
Methamphetamine—Dyspepsia—Estradiol—prostate cancer	0.000355	0.00386	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Estradiol—prostate cancer	0.000348	0.00379	CcSEcCtD
Methamphetamine—Diarrhoea—Goserelin—prostate cancer	0.000348	0.00379	CcSEcCtD
Methamphetamine—Constipation—Estradiol—prostate cancer	0.000345	0.00375	CcSEcCtD
Methamphetamine—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000345	0.00375	CcSEcCtD
Methamphetamine—Dizziness—Goserelin—prostate cancer	0.000336	0.00366	CcSEcCtD
Methamphetamine—CYP2D6—testis—prostate cancer	0.000334	0.00813	CbGeAlD
Methamphetamine—Dizziness—Conjugated Estrogens—prostate cancer	0.000333	0.00362	CcSEcCtD
Methamphetamine—Dyspepsia—Mitoxantrone—prostate cancer	0.000331	0.0036	CcSEcCtD
Methamphetamine—Constipation—Mitoxantrone—prostate cancer	0.000321	0.00349	CcSEcCtD
Methamphetamine—Urticaria—Estradiol—prostate cancer	0.00032	0.00348	CcSEcCtD
Methamphetamine—Headache—Goserelin—prostate cancer	0.000319	0.00347	CcSEcCtD
Methamphetamine—Headache—Conjugated Estrogens—prostate cancer	0.000316	0.00343	CcSEcCtD
Methamphetamine—ADRA2A—lymph node—prostate cancer	0.000313	0.00761	CbGeAlD
Methamphetamine—Tachycardia—Etoposide—prostate cancer	0.000305	0.00332	CcSEcCtD
Methamphetamine—Dexfenfluramine—CYP2E1—prostate cancer	0.000299	0.0489	CrCbGaD
Methamphetamine—Urticaria—Mitoxantrone—prostate cancer	0.000298	0.00325	CcSEcCtD
Methamphetamine—Hypersensitivity—Estradiol—prostate cancer	0.000297	0.00323	CcSEcCtD
Methamphetamine—Dexfenfluramine—CYP2C19—prostate cancer	0.000296	0.0484	CrCbGaD
Methamphetamine—Tremor—Capecitabine—prostate cancer	0.000289	0.00314	CcSEcCtD
Methamphetamine—Palpitations—Docetaxel—prostate cancer	0.000281	0.00306	CcSEcCtD
Methamphetamine—Amphetamine—SLC22A3—prostate cancer	0.000278	0.0455	CrCbGaD
Methamphetamine—Hypersensitivity—Mitoxantrone—prostate cancer	0.000277	0.00301	CcSEcCtD
Methamphetamine—Diarrhoea—Estradiol—prostate cancer	0.000276	0.003	CcSEcCtD
Methamphetamine—Palpitations—Capecitabine—prostate cancer	0.000272	0.00296	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Etoposide—prostate cancer	0.00027	0.00293	CcSEcCtD
Methamphetamine—Constipation—Etoposide—prostate cancer	0.000267	0.00291	CcSEcCtD
Methamphetamine—Dizziness—Estradiol—prostate cancer	0.000267	0.0029	CcSEcCtD
Methamphetamine—Diarrhoea—Mitoxantrone—prostate cancer	0.000257	0.0028	CcSEcCtD
Methamphetamine—Tachycardia—Docetaxel—prostate cancer	0.000253	0.00276	CcSEcCtD
Methamphetamine—Headache—Estradiol—prostate cancer	0.000253	0.00275	CcSEcCtD
Methamphetamine—Agitation—Prednisone—prostate cancer	0.000252	0.00274	CcSEcCtD
Methamphetamine—Urticaria—Etoposide—prostate cancer	0.000248	0.0027	CcSEcCtD
Methamphetamine—Tachycardia—Capecitabine—prostate cancer	0.000245	0.00267	CcSEcCtD
Methamphetamine—Headache—Mitoxantrone—prostate cancer	0.000235	0.00256	CcSEcCtD
Methamphetamine—Insomnia—Docetaxel—prostate cancer	0.000235	0.00255	CcSEcCtD
Methamphetamine—Hypersensitivity—Etoposide—prostate cancer	0.00023	0.0025	CcSEcCtD
Methamphetamine—Dyspepsia—Docetaxel—prostate cancer	0.000229	0.00249	CcSEcCtD
Methamphetamine—Insomnia—Capecitabine—prostate cancer	0.000227	0.00247	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000224	0.00244	CcSEcCtD
Methamphetamine—Constipation—Docetaxel—prostate cancer	0.000222	0.00242	CcSEcCtD
Methamphetamine—Dyspepsia—Capecitabine—prostate cancer	0.000221	0.00241	CcSEcCtD
Methamphetamine—Tachycardia—Prednisone—prostate cancer	0.000219	0.00238	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000217	0.00236	CcSEcCtD
Methamphetamine—Constipation—Capecitabine—prostate cancer	0.000215	0.00234	CcSEcCtD
Methamphetamine—Diarrhoea—Etoposide—prostate cancer	0.000214	0.00233	CcSEcCtD
Methamphetamine—Ephedrine—ADRB2—prostate cancer	0.000207	0.0338	CrCbGaD
Methamphetamine—Dizziness—Etoposide—prostate cancer	0.000207	0.00225	CcSEcCtD
Methamphetamine—Insomnia—Prednisone—prostate cancer	0.000203	0.0022	CcSEcCtD
Methamphetamine—Urticaria—Capecitabine—prostate cancer	0.0002	0.00217	CcSEcCtD
Methamphetamine—Agitation—Epirubicin—prostate cancer	0.000197	0.00215	CcSEcCtD
Methamphetamine—Dyspepsia—Prednisone—prostate cancer	0.000197	0.00214	CcSEcCtD
Methamphetamine—Headache—Etoposide—prostate cancer	0.000196	0.00213	CcSEcCtD
Methamphetamine—Constipation—Prednisone—prostate cancer	0.000191	0.00208	CcSEcCtD
Methamphetamine—Hypersensitivity—Docetaxel—prostate cancer	0.000191	0.00208	CcSEcCtD
Methamphetamine—Palpitations—Epirubicin—prostate cancer	0.00019	0.00206	CcSEcCtD
Methamphetamine—Selegiline—CYP2A6—prostate cancer	0.000188	0.0306	CrCbGaD
Methamphetamine—Phenylpropanolamine—ADRB2—prostate cancer	0.000186	0.0303	CrCbGaD
Methamphetamine—Hypersensitivity—Capecitabine—prostate cancer	0.000185	0.00201	CcSEcCtD
Methamphetamine—Agitation—Doxorubicin—prostate cancer	0.000182	0.00199	CcSEcCtD
Methamphetamine—Urticaria—Prednisone—prostate cancer	0.000178	0.00194	CcSEcCtD
Methamphetamine—Diarrhoea—Docetaxel—prostate cancer	0.000178	0.00193	CcSEcCtD
Methamphetamine—Palpitations—Doxorubicin—prostate cancer	0.000175	0.00191	CcSEcCtD
Methamphetamine—Nateglinide—CYP3A5—prostate cancer	0.000173	0.0283	CrCbGaD
Methamphetamine—Diarrhoea—Capecitabine—prostate cancer	0.000172	0.00187	CcSEcCtD
Methamphetamine—Dizziness—Docetaxel—prostate cancer	0.000172	0.00187	CcSEcCtD
Methamphetamine—Tachycardia—Epirubicin—prostate cancer	0.000171	0.00186	CcSEcCtD
Methamphetamine—Phenelzine—CYP3A5—prostate cancer	0.000171	0.0279	CrCbGaD
Methamphetamine—Dizziness—Capecitabine—prostate cancer	0.000166	0.00181	CcSEcCtD
Methamphetamine—Hypersensitivity—Prednisone—prostate cancer	0.000165	0.00179	CcSEcCtD
Methamphetamine—Headache—Docetaxel—prostate cancer	0.000163	0.00177	CcSEcCtD
Methamphetamine—Insomnia—Epirubicin—prostate cancer	0.000158	0.00172	CcSEcCtD
Methamphetamine—Tachycardia—Doxorubicin—prostate cancer	0.000158	0.00172	CcSEcCtD
Methamphetamine—Headache—Capecitabine—prostate cancer	0.000157	0.00171	CcSEcCtD
Methamphetamine—Pseudoephedrine—ADRB2—prostate cancer	0.000157	0.0256	CrCbGaD
Methamphetamine—Amphetamine—CYP2A6—prostate cancer	0.000156	0.0255	CrCbGaD
Methamphetamine—Dyspepsia—Epirubicin—prostate cancer	0.000154	0.00168	CcSEcCtD
Methamphetamine—Diarrhoea—Prednisone—prostate cancer	0.000153	0.00167	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000151	0.00164	CcSEcCtD
Methamphetamine—Constipation—Epirubicin—prostate cancer	0.00015	0.00163	CcSEcCtD
Methamphetamine—Dizziness—Prednisone—prostate cancer	0.000148	0.00161	CcSEcCtD
Methamphetamine—Insomnia—Doxorubicin—prostate cancer	0.000147	0.00159	CcSEcCtD
Methamphetamine—Dyspepsia—Doxorubicin—prostate cancer	0.000143	0.00155	CcSEcCtD
Methamphetamine—Headache—Prednisone—prostate cancer	0.00014	0.00153	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.00014	0.00152	CcSEcCtD
Methamphetamine—Urticaria—Epirubicin—prostate cancer	0.000139	0.00151	CcSEcCtD
Methamphetamine—Benzyl alcohol—CYP2E1—prostate cancer	0.000139	0.0227	CrCbGaD
Methamphetamine—Constipation—Doxorubicin—prostate cancer	0.000139	0.00151	CcSEcCtD
Methamphetamine—Benzyl alcohol—CYP1A1—prostate cancer	0.000137	0.0224	CrCbGaD
Methamphetamine—Selegiline—CYP2E1—prostate cancer	0.000133	0.0218	CrCbGaD
Methamphetamine—Selegiline—CYP2C19—prostate cancer	0.000132	0.0215	CrCbGaD
Methamphetamine—Hypersensitivity—Epirubicin—prostate cancer	0.000129	0.0014	CcSEcCtD
Methamphetamine—Urticaria—Doxorubicin—prostate cancer	0.000129	0.0014	CcSEcCtD
Methamphetamine—Diarrhoea—Epirubicin—prostate cancer	0.00012	0.0013	CcSEcCtD
Methamphetamine—Hypersensitivity—Doxorubicin—prostate cancer	0.000119	0.0013	CcSEcCtD
Methamphetamine—Phenelzine—CYP2E1—prostate cancer	0.000117	0.0192	CrCbGaD
Methamphetamine—Phenelzine—CYP2C19—prostate cancer	0.000116	0.019	CrCbGaD
Methamphetamine—Dizziness—Epirubicin—prostate cancer	0.000116	0.00126	CcSEcCtD
Methamphetamine—Diarrhoea—Doxorubicin—prostate cancer	0.000111	0.00121	CcSEcCtD
Methamphetamine—Headache—Epirubicin—prostate cancer	0.00011	0.00119	CcSEcCtD
Methamphetamine—Dizziness—Doxorubicin—prostate cancer	0.000107	0.00117	CcSEcCtD
Methamphetamine—Headache—Doxorubicin—prostate cancer	0.000102	0.0011	CcSEcCtD
Methamphetamine—Benzyl alcohol—CYP3A4—prostate cancer	8.74e-05	0.0143	CrCbGaD
Methamphetamine—Selegiline—CYP3A4—prostate cancer	8.39e-05	0.0137	CrCbGaD
Methamphetamine—Nateglinide—CYP3A4—prostate cancer	7.5e-05	0.0122	CrCbGaD
Methamphetamine—Phenelzine—CYP3A4—prostate cancer	7.39e-05	0.0121	CrCbGaD
Methamphetamine—Benzphetamine—CYP3A4—prostate cancer	6.41e-05	0.0105	CrCbGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—JAK2—prostate cancer	5.2e-06	3.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—KRAS—prostate cancer	5.19e-06	3.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—MAP2K1—prostate cancer	5.18e-06	3.05e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HIF1A—prostate cancer	5.18e-06	3.05e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CD—prostate cancer	5.15e-06	3.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VAV3—prostate cancer	5.14e-06	3.03e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NCOA2—prostate cancer	5.14e-06	3.03e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—NOS3—prostate cancer	5.14e-06	3.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—AKT1—prostate cancer	5.13e-06	3.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CG—prostate cancer	5.09e-06	3e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL2—prostate cancer	5.07e-06	2.99e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TGFBR2—prostate cancer	5.07e-06	2.99e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TERT—prostate cancer	5.06e-06	2.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—LEP—prostate cancer	5.05e-06	2.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CAV1—prostate cancer	5.01e-06	2.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ITPR1—prostate cancer	4.99e-06	2.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KDR—prostate cancer	4.95e-06	2.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PIK3CB—prostate cancer	4.94e-06	2.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—MTHFR—prostate cancer	4.92e-06	2.9e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SLC5A5—prostate cancer	4.9e-06	2.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HIF1A—prostate cancer	4.83e-06	2.85e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PPARA—prostate cancer	4.83e-06	2.85e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ESR1—prostate cancer	4.82e-06	2.84e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—INS—prostate cancer	4.82e-06	2.84e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—AKT1—prostate cancer	4.79e-06	2.83e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP2E1—prostate cancer	4.79e-06	2.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF1R—prostate cancer	4.77e-06	2.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—PIK3CA—prostate cancer	4.77e-06	2.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCL8—prostate cancer	4.75e-06	2.8e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3CB—prostate cancer	4.74e-06	2.8e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NQO1—prostate cancer	4.74e-06	2.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—JAK2—prostate cancer	4.72e-06	2.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CREBBP—prostate cancer	4.72e-06	2.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—LEP—prostate cancer	4.72e-06	2.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—BAD—prostate cancer	4.71e-06	2.77e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTGS2—prostate cancer	4.7e-06	2.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CAV1—prostate cancer	4.68e-06	2.76e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TH—prostate cancer	4.67e-06	2.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KDR—prostate cancer	4.62e-06	2.73e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP3A4—prostate cancer	4.62e-06	2.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TP53—prostate cancer	4.61e-06	2.72e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PIK3CA—prostate cancer	4.61e-06	2.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—LPL—prostate cancer	4.57e-06	2.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APC—prostate cancer	4.56e-06	2.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CG—prostate cancer	4.56e-06	2.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CAV1—prostate cancer	4.54e-06	2.68e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP1B1—prostate cancer	4.54e-06	2.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—IL2—prostate cancer	4.54e-06	2.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PDGFRB—prostate cancer	4.53e-06	2.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EGF—prostate cancer	4.51e-06	2.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IRS1—prostate cancer	4.51e-06	2.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ESR1—prostate cancer	4.51e-06	2.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CB—prostate cancer	4.49e-06	2.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CD—prostate cancer	4.48e-06	2.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ITGB3—prostate cancer	4.42e-06	2.6e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GGT1—prostate cancer	4.4e-06	2.59e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—BAD—prostate cancer	4.4e-06	2.59e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—GSK3B—prostate cancer	4.38e-06	2.58e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NCOA1—prostate cancer	4.33e-06	2.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—INS—prostate cancer	4.32e-06	2.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCL8—prostate cancer	4.31e-06	2.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ERBB3—prostate cancer	4.28e-06	2.53e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGFR2—prostate cancer	4.28e-06	2.52e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP19A1—prostate cancer	4.27e-06	2.52e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APC—prostate cancer	4.26e-06	2.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CG—prostate cancer	4.26e-06	2.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—NOS3—prostate cancer	4.23e-06	2.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CREBBP—prostate cancer	4.23e-06	2.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EGF—prostate cancer	4.21e-06	2.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IRS1—prostate cancer	4.21e-06	2.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IGF1—prostate cancer	4.17e-06	2.46e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—EGFR—prostate cancer	4.15e-06	2.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CG—prostate cancer	4.14e-06	2.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL2—prostate cancer	4.12e-06	2.43e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—RXRA—prostate cancer	4.12e-06	2.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TERT—prostate cancer	4.11e-06	2.42e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTEN—prostate cancer	4.1e-06	2.42e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—GSK3B—prostate cancer	4.09e-06	2.41e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAP2K1—prostate cancer	4.03e-06	2.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—INS—prostate cancer	4.03e-06	2.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CD—prostate cancer	4.01e-06	2.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—PIK3CA—prostate cancer	3.97e-06	2.34e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—COMT—prostate cancer	3.97e-06	2.34e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SERPINE1—prostate cancer	3.96e-06	2.34e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTP1—prostate cancer	3.95e-06	2.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CREBBP—prostate cancer	3.95e-06	2.33e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HIF1A—prostate cancer	3.93e-06	2.31e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—KRAS—prostate cancer	3.92e-06	2.31e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—INS—prostate cancer	3.92e-06	2.31e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—EP300—prostate cancer	3.91e-06	2.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CB—prostate cancer	3.9e-06	2.3e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PIK3CA—prostate cancer	3.9e-06	2.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IGF1—prostate cancer	3.9e-06	2.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—AKT1—prostate cancer	3.89e-06	2.3e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ITPR1—prostate cancer	3.89e-06	2.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—EGFR—prostate cancer	3.88e-06	2.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTGS2—prostate cancer	3.87e-06	2.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FGF2—prostate cancer	3.84e-06	2.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CREBBP—prostate cancer	3.84e-06	2.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—LEP—prostate cancer	3.83e-06	2.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CAV1—prostate cancer	3.8e-06	2.24e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NOS3—prostate cancer	3.78e-06	2.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAP2K1—prostate cancer	3.77e-06	2.22e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—AKT1—prostate cancer	3.77e-06	2.22e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KDR—prostate cancer	3.76e-06	2.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CD—prostate cancer	3.74e-06	2.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—PIK3CA—prostate cancer	3.71e-06	2.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SERPINE1—prostate cancer	3.7e-06	2.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—JAK2—prostate cancer	3.68e-06	2.17e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TYMS—prostate cancer	3.67e-06	2.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—KRAS—prostate cancer	3.67e-06	2.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ESR1—prostate cancer	3.66e-06	2.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CD—prostate cancer	3.64e-06	2.14e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTM1—prostate cancer	3.63e-06	2.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—PIK3CA—prostate cancer	3.61e-06	2.13e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MDM2—prostate cancer	3.59e-06	2.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FGF2—prostate cancer	3.58e-06	2.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—BAD—prostate cancer	3.57e-06	2.11e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—LPL—prostate cancer	3.56e-06	2.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ERBB2—prostate cancer	3.54e-06	2.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NOS3—prostate cancer	3.54e-06	2.08e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CB—prostate cancer	3.49e-06	2.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APC—prostate cancer	3.46e-06	2.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	3.46e-06	2.04e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP1A1—prostate cancer	3.44e-06	2.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—JAK2—prostate cancer	3.44e-06	2.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—NOS3—prostate cancer	3.43e-06	2.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IRS1—prostate cancer	3.42e-06	2.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EGF—prostate cancer	3.42e-06	2.02e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ERCC2—prostate cancer	3.41e-06	2.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTEN—prostate cancer	3.37e-06	1.99e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PIK3CA—prostate cancer	3.37e-06	1.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCL8—prostate cancer	3.36e-06	1.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MDM2—prostate cancer	3.35e-06	1.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	3.32e-06	1.96e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ERBB2—prostate cancer	3.31e-06	1.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CDKN1B—prostate cancer	3.28e-06	1.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—INS—prostate cancer	3.27e-06	1.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CB—prostate cancer	3.26e-06	1.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—AKT1—prostate cancer	3.24e-06	1.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—EP300—prostate cancer	3.22e-06	1.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CASP3—prostate cancer	3.21e-06	1.89e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MTHFR—prostate cancer	3.21e-06	1.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL2—prostate cancer	3.21e-06	1.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	3.21e-06	1.89e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL6—prostate cancer	3.19e-06	1.88e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—AKT1—prostate cancer	3.19e-06	1.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CB—prostate cancer	3.17e-06	1.87e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF1—prostate cancer	3.17e-06	1.87e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	3.15e-06	1.86e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PPARA—prostate cancer	3.15e-06	1.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTGS2—prostate cancer	3.14e-06	1.85e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCL8—prostate cancer	3.14e-06	1.85e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCND1—prostate cancer	3.13e-06	1.84e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CTNNB1—prostate cancer	3.1e-06	1.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CDKN1B—prostate cancer	3.06e-06	1.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	3.06e-06	1.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	3.04e-06	1.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MMP9—prostate cancer	3.04e-06	1.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—AKT1—prostate cancer	3.03e-06	1.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CDKN1A—prostate cancer	3.03e-06	1.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PTEN—prostate cancer	3.02e-06	1.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	3.01e-06	1.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	3.01e-06	1.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CASP3—prostate cancer	3e-06	1.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL2—prostate cancer	3e-06	1.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6—prostate cancer	2.98e-06	1.76e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	2.98e-06	1.75e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CAV1—prostate cancer	2.96e-06	1.74e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—AKT1—prostate cancer	2.95e-06	1.74e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCND1—prostate cancer	2.92e-06	1.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGF2—prostate cancer	2.91e-06	1.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	2.89e-06	1.71e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3CA—prostate cancer	2.89e-06	1.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EP300—prostate cancer	2.88e-06	1.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NOS3—prostate cancer	2.87e-06	1.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MMP9—prostate cancer	2.84e-06	1.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	2.83e-06	1.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PTEN—prostate cancer	2.82e-06	1.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SRC—prostate cancer	2.8e-06	1.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—JAK2—prostate cancer	2.79e-06	1.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	2.75e-06	1.62e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTEN—prostate cancer	2.74e-06	1.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	2.74e-06	1.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	2.73e-06	1.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MDM2—prostate cancer	2.72e-06	1.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—STAT3—prostate cancer	2.7e-06	1.59e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CG—prostate cancer	2.7e-06	1.59e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EP300—prostate cancer	2.69e-06	1.59e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	2.69e-06	1.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	2.65e-06	1.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SRC—prostate cancer	2.62e-06	1.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—EP300—prostate cancer	2.61e-06	1.54e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—INS—prostate cancer	2.55e-06	1.5e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	2.55e-06	1.5e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	2.55e-06	1.5e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—STAT3—prostate cancer	2.52e-06	1.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MYC—prostate cancer	2.51e-06	1.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	2.5e-06	1.48e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CREBBP—prostate cancer	2.5e-06	1.47e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	2.49e-06	1.47e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	2.46e-06	1.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EGFR—prostate cancer	2.45e-06	1.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CASP3—prostate cancer	2.44e-06	1.44e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL2—prostate cancer	2.43e-06	1.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6—prostate cancer	2.42e-06	1.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CA—prostate cancer	2.38e-06	1.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCND1—prostate cancer	2.37e-06	1.4e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CD—prostate cancer	2.37e-06	1.4e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—AKT1—prostate cancer	2.36e-06	1.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	2.35e-06	1.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MYC—prostate cancer	2.34e-06	1.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	2.34e-06	1.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KRAS—prostate cancer	2.32e-06	1.37e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MMP9—prostate cancer	2.3e-06	1.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	2.3e-06	1.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EGFR—prostate cancer	2.29e-06	1.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PTEN—prostate cancer	2.29e-06	1.35e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NOS3—prostate cancer	2.24e-06	1.32e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	2.23e-06	1.32e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EP300—prostate cancer	2.18e-06	1.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KRAS—prostate cancer	2.17e-06	1.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	2.13e-06	1.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SRC—prostate cancer	2.12e-06	1.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	2.07e-06	1.22e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CB—prostate cancer	2.07e-06	1.22e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TP53—prostate cancer	2.06e-06	1.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—STAT3—prostate cancer	2.05e-06	1.21e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTGS2—prostate cancer	2.05e-06	1.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	1.99e-06	1.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—AKT1—prostate cancer	1.94e-06	1.15e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CA—prostate cancer	1.93e-06	1.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TP53—prostate cancer	1.92e-06	1.13e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MYC—prostate cancer	1.9e-06	1.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	1.9e-06	1.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6—prostate cancer	1.89e-06	1.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EGFR—prostate cancer	1.86e-06	1.1e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTEN—prostate cancer	1.79e-06	1.05e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6—prostate cancer	1.76e-06	1.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KRAS—prostate cancer	1.76e-06	1.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AKT1—prostate cancer	1.74e-06	1.03e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—EP300—prostate cancer	1.7e-06	1e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AKT1—prostate cancer	1.63e-06	9.58e-06	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	1.62e-06	9.52e-06	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—AKT1—prostate cancer	1.58e-06	9.31e-06	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TP53—prostate cancer	1.56e-06	9.21e-06	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6—prostate cancer	1.43e-06	8.43e-06	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AKT1—prostate cancer	1.32e-06	7.78e-06	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.26e-06	7.42e-06	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—AKT1—prostate cancer	1.03e-06	6.06e-06	CbGpPWpGaD
